Global Anti-diabetic Drugs Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR 10.5% during forecast period.
Global Anti-diabetic Drugs Market Overview:

Diabetes is a condition in which the levels of blood glucose are abnormally high. Glucose is derived from the food consumed. Anti-diabetic drugs are medications designed to maintain diabetes and regulate blood glucose levels.
Global Anti-diabetic Drugs Market Dynamics:

Rising prevalence of diabetes globally is the major driving factor for the market growth.

Increasing occurrence of both Type I and Type II diabetes is expected to drive market growth during the forecast period. Also, the increasing obese population is further expected to drive the market growth. In 2019, 31.3% of the 511 million people were diagnosed with diabetes. It estimated that Diabetes was the eighth leading cause of death in the world, which caused 4.2 million deaths in 2019. The International Diabetes Federation states that diabetes and related disorders are expected to rise over the forecast period as a result of changing lifestyles and rising geriatric populations globally. It also states that the prevalence of diabetes globally is expected to affect 552 million people by 2030. As glucose resistance worsens with age, geriatric patients are more likely to take anti-diabetic drugs. This rapid increase is anticipated to aid the market growth. Other factors such as rising demand for oral anti-diabetic drugs, unhealthy diet habits, sedentary lifestyle, and high-stress levels are also boosting the market growth. Furthermore, technological advancements, increased investment in drug production, increased healthcare expenditure, development of new novel drug candidates, and medical reimbursement policies are all expected to contribute to the market's growth.

Certain factors, such as the high cost of anti-diabetic drugs, strict regulatory conditions, and a lengthy approval process may limit the market growth. However, ongoing research and a large market opportunity will help the anti-diabetic market grow over the forecast period.

The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing RD activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Anti-diabetic Drugs Market Segment Analysis:

The Global Anti-diabetic Drugs Market is segmented on the basis of drug class, diabetes type and distribution channel.

Based on Drug Class, the Insulin segment held the largest market share in the year 2019 and it is anticipated to grow at a CAGR of 4.5% during the forecast period. The growth of this can be attributed to the widespread usage of the product, as well as the effective therapeutic properties associated with it. Furthermore, the launch of new products and the promotion of other drug candidates currently in the pipeline will encourage segment growth.

The Biguanides segment is expected to hold the second-largest share. Biguanides, such as Metformin, are often used as a first-line anti-diabetic treatment. These medications are often used to treat type II diabetes, and they work by causing the beta cells in the pancreas to release more insulin.

Global Anti-diabetic Drugs Market

To know about the Research Methodology :- Request Free Sample Report
Global Anti-diabetic Drugs Market Regional Insights:

Global Anti-diabetic Drugs Market 1
North America is expected to dominate the global market throughout the forecast period.

North America region accounted for a dominant share of 32% in 2019. Factors such as rapidly rising obese populations, consumption of alcohol and smoking favorable government reimbursement policies, rising healthcare awareness, and the presence of key product manufacturers, create the potential growth opportunities for the market growth in the region. The American Diabetes Association’s published report states that, approximately 34.2 million Americans were affected by diabetes in 2018, and approximately 88 million people in the country had prediabetes.
Asia Pacific is expected to witness highest growth during the forecast period.

The factors aiding to the market growth in region is the rising consumer disposable income, rise in healthcare expenses, and the increasing prevalence of type I and type II diabetes. Also, the easy availability of cheaper OTC (over-the-counter) anti-diabetic drugs in Asia Pacific countries such as India, China, and South Korea will also contribute to the region's anti-diabetic drug market growth.

The report also helps in understanding Global Anti-diabetic Drugs Market dynamics, structure by analyzing the market segments and project the Global Anti-diabetic Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-diabetic Drugs Market make the report investor’s guide.
Global Anti-diabetic Drugs Market, Key Developments:

• In March 2020, the generic versions of AstraZeneca's proprietary anti-diabetes brand, Farxig, were launched by the Indian company NatcoPharma. The generic drug will be sold under the name Dapnat and will be available in 5mg and 10mg tablet forms.
• In January 2020, Eli Lilly and Co. and Boehringer Ingelheim received FDA approval for the first oral therapy for the treatment of Type 2 diabetes that combines three drugs into one tablet. The combination drug includes linagliptin, an inhibitor of DPP IV, empagliflozin, an inhibitor of SGLT2, and metformin hydrochloride extended-release.
• Mankind Pharmaceuticals and Glenmark Pharmaceuticals signed a joint agreement in December 2019 to market remoglifozin, an anti-diabetic medication, which aided to the both company’s growth in Asia Pacific region.
Global Anti-diabetic Drugs Market Scope: Inquire before buying

Global Anti-diabetic Drugs Market 2
Global Anti-diabetic Drugs Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC
Global Anti-diabetic Drugs Market, Key players:

• AstraZeneca
• Novartis AG
• Johnson Johnson
• Merck Co. Inc.
• Pfizer
• Sanofi
• Novo Nordisk A/S
• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Abbott
• Boehringer Ingelheim International GmbH
• Oramed Pharmaceuticals
• Takeda Pharmaceuticals
• Halozyme Therapeutics
• Bristol-Myers Squibb
• Biocon
• Wockhardt